MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiome

CAMBRIDGE, Mass., Oct. 28, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotec

Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market

Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including

Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consisten

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.90) per share which missed the analyst consen

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing P

HC Wainwright & Co. analyst Andrew S. Fein reiterates MetaVia (NASDAQ:MTVA) with a Buy and ma

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 m

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 m

CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotec

POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a lead

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT

DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evide

DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evide

Solidion Technology, Inc. (NASDAQ: STI) rose 50.55% in pre-market trading on Friday after announcing

MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiomet

CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech

48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauExp

48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Ex

Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data

Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data

MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing

MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing

The paper, entitled, "A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic St

CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech

Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial

HC Wainwright & Co. analyst Andrew S. Fein reiterates MetaVia (NASDAQ:MTVA) with a Buy and ma

Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR1

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.79) per share which missed the analyst consen

48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, I

MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiomet

CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech

16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obe

48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Im

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in O

MetaVia Inc. (NASDAQ: MTVA - Get Free Report) saw a significant growth in short interest in February